Anonymous: "UCB Proof of Concept Study in Patients With Primary Sjogren's Syndrome", , 18 November 2015 (2015-11-18), XP002758921, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NC T02610543?term=ucb_5857&rank=3 [retrieved on 2016-06-17] (B1)

BAUDOUIN C ET AL: "Current treatments of xerophthalmia in Sjögren's syndrome. // Traitements actuels de la xérophthalmia in Sjögren's syndrome", REVUE DE MEDECINE INTERNE, CMR, ASNIERES, FR, vol. 25, no. 5, 1 May 2004 (2004-05-01), pages 376-382, XP002684654, ISSN: 0248-8663, DOI: 10.1016/J.REVMED.2003.10.009 (B1)

YAGER, N. ET AL.: "Inhibition of phosphatidylinositol-3-kinase delta reduces psoriatic T cell activity", Journal of Investigative Dermatology, vol. 134, no. 2, 418, July 2014 (2014-07), page s73, XP002758922, Retrieved from the Internet: URL:http://ac.els-cdn.com/S0022202X1537016 0/1-s2.0-S0022202X15370160-main.pdf?_tid=0 5c9f640-3492-11e6-b6f6-00000aab0f6b&acdnat =1466171424_7b2a8ae7df72912d692f8f848363d1 97 [retrieved on 2016-06-17] (B1)

SIMON BOWMAN ET AL: "Biologic treatments in Sjögren's syndrome", PRESSE MEDICALE., vol. 41, no. 9, 1 September 2012 (2012-09-01), pages e495-e509, XP055281488, FR ISSN: 0755-4982, DOI: 10.1016/j.lpm.2012.05.024 (B1)

WO-A1-2012/032334 (B1)

NAYAR, S ET AL.: "Phosphatidylinositol-3-kinase Delta Parthway a Novel Therapeutic Target for Sjögren's Syndrome", ARTHRITIS AND RHEUMATOLOGY, vol. 67, no. 10, 1053, October 2015 (2015-10), XP002758920, (B1)